Primary FDA-Approved Indications
Primary indications include ductus arteriosus closure and specialist rheumatology cases.
Patent ductus arteriosus
FDA ApprovedPremature neonatesRandomized trials
Evidence Sources
()
Juvenile idiopathic arthritis (refractory)
FDA ApprovedChildrenClinical studies